Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588932 · ClinicalTrials.gov registry record · Early Phase 1
Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors
A Early Phase 1 study, sponsored by Spaulding Rehabilitation Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07588932 is a Early Phase 1 study that has not yet begun recruiting, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 50 participants.
The verdict
NCT07588932, a Early Phase 1 study, has not yet begun recruiting, sponsored by Spaulding Rehabilitation Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this trial is to study if the concomitant administration of Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) can help stroke survivors make greater gains in movement and recovery during robot-assisted arm and hand rehabilitation.
Interventions
- DRUG Telmisartan, Metformin, Cilostazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2028-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07588932
The ClinicalTrials.gov registry entry for NCT07588932 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spaulding Rehabilitation Hospital, which has 101 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telmisartan, Metformin, Cilostazol is the first listed.
NCT07588932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07588932 about?
NCT07588932 is a clinical study titled "Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors". The goal of this trial is to study if the concomitant administration of Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) can help stroke survivors make greater gains in movement and recovery during robot-assisted arm and hand rehabilitation.
What is the current status of trial NCT07588932?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-05-18. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07588932?
The interventions under investigation include: Telmisartan, Metformin, Cilostazol (DRUG).
Who is sponsoring clinical trial NCT07588932?
This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.